Salarius Pharmaceuticals' Decoy Unit Partners With Texas Biomed on Flu Inhibitor Testing

MT Newswires Live12-01

Salarius Pharmaceuticals (SLRX) said Monday its unit Decoy Therapeutics and the Texas Biomedical Research Institute are partnering to run in vitro testing of Decoy's influenza inhibitors, including those targeting H5N1 avian flu.

Financial terms weren't provided.

Salarius said the partnership follows its recent underwritten public offering that raised $8 million and consumated a previously announced merger with Decoy Therapeutics, and is expected to support plans to advance Decoy's antiviral pipeline.

Decoy expects to move its lead pan-coronavirus program toward an Investigational New Drug Application filing with the US Food and Drug Administration in the next year, Salarius said.

Shares of the company were down 0.5% in recent early Monday trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588443775?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-01 22:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588443775","market":"sg","top_or_hot":-1,"title":"Salarius Pharmaceuticals' Decoy Unit Partners With Texas Biomed on Flu Inhibitor Testing","media":"MT Newswires Live","content":"<html><body><p> Salarius Pharmaceuticals (SLRX) said Monday its unit Decoy <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> and the Texas Biomedical Research Institute are partnering to run in vitro testing of Decoy's influenza inhibitors, including those targeting H5N1 avian flu.</p><p>Financial terms weren't provided.</p><p>Salarius said the partnership follows its recent underwritten public offering that raised $8 million and consumated a previously announced merger with Decoy Therapeutics, and is expected to support plans to advance Decoy's antiviral pipeline.</p><p>Decoy expects to move its lead pan-coronavirus program toward an Investigational New Drug Application filing with the US Food and Drug Administration in the next year, Salarius said.</p><p>Shares of the company were down 0.5% in recent early Monday trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Salarius Pharmaceuticals' Decoy Unit Partners With Texas Biomed on Flu Inhibitor Testing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSalarius Pharmaceuticals' Decoy Unit Partners With Texas Biomed on Flu Inhibitor Testing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-01 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Salarius Pharmaceuticals (SLRX) said Monday its unit Decoy <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> and the Texas Biomedical Research Institute are partnering to run in vitro testing of Decoy's influenza inhibitors, including those targeting H5N1 avian flu.</p><p>Financial terms weren't provided.</p><p>Salarius said the partnership follows its recent underwritten public offering that raised $8 million and consumated a previously announced merger with Decoy Therapeutics, and is expected to support plans to advance Decoy's antiviral pipeline.</p><p>Decoy expects to move its lead pan-coronavirus program toward an Investigational New Drug Application filing with the US Food and Drug Administration in the next year, Salarius said.</p><p>Shares of the company were down 0.5% in recent early Monday trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SLRX","symbol_name":"Salarius Pharmaceuticals Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2588443775","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588443775","pubTimestamp":1764599928,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Salarius Pharmaceuticals  said Monday its unit Decoy Therapeutics and the Texas Biomedical Research Institute are partnering to run in vitro testing of Decoy's influenza inhibitors, including those targeting H5N1 avian flu.Financial terms weren't provided.Salarius said the partnership follows its recent underwritten public offering that raised $8 million and consumated a previously announced merger with Decoy Therapeutics, and is expected to support plans to advance Decoy's antiviral pipeline.Decoy expects to move its lead pan-coronavirus program toward an Investigational New Drug Application filing with the US Food and Drug Administration in the next year, Salarius said.Shares of the company were down 0.5% in recent early Monday trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SLRX":"Salarius Pharmaceuticals Inc","BK4139":"生物科技"},"translate_title":"Salarius Pharmaceuticals的诱饵部门与Texas Biomed合作进行流感抑制剂测试","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLRX":1},"content_text":"Salarius Pharmaceuticals (SLRX) said Monday its unit Decoy Therapeutics and the Texas Biomedical Research Institute are partnering to run in vitro testing of Decoy's influenza inhibitors, including those targeting H5N1 avian flu.Financial terms weren't provided.Salarius said the partnership follows its recent underwritten public offering that raised $8 million and consumated a previously announced merger with Decoy Therapeutics, and is expected to support plans to advance Decoy's antiviral pipeline.Decoy expects to move its lead pan-coronavirus program toward an Investigational New Drug Application filing with the US Food and Drug Administration in the next year, Salarius said.Shares of the company were down 0.5% in recent early Monday trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588443775","isCrawlerRequest":true}